Tribal Group PLC
29 November 2002
29 November 2002
Tribal Group awarded £8m healthcare architectural contract
Tribal Group plc, the provider of professional support and consultancy services,
today announces the award of a major healthcare architectural contract.
Tribal are appointed by Skanska Innisfree, the consortium, as Project Architect
on the £330 million new 1,212-bed acute hospital and clinical sciences teaching
and research facility at Walsgrave for University Hospitals Coventry and
Warwickshire NHS Trust. The consortium will also provide a 130-bed mental
health unit for Coventry Primary Care Trust.
Tribal's contract is valued at £8 million over the three-year construction
period.
Henry Pitman, Chief Executive of Tribal commented:
'We are delighted to have been awarded this prestigious contract, the largest
won by Tribal to date. We are confident that it will lead to other similar
contracts in the health sector.'
For further information please contact:
Tribal Group plc - Henry Pitman, Chief Executive 01285 886020
END
This information is provided by RNS
The company news service from the London Stock Exchange
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.